# US Cancer Diagnostics Market

> United States Cancer Diagnostics Market Research Report: Size, Share, Trend Analysis - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.72%
- **2024:** $ 46.35 Billion
- **2025:** $ 49.93 Billion
- **2035:** $ 105 Billion
- **Key Players:** Roche (CH), Abbott (US), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Bristol-Myers Squibb (US), Illumina (US), Agilent Technologies (US), Qiagen (DE), Hologic (US)

**Report ID:** MRFR/MED/14298-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-cancer-diagnostics-market-15825

---

## Market Summary

## US Cancer Diagnostics Market Highlighted Trends & Dynamics

The demand for cancer diagnostics in the United States is increasing due to several factors that indicate the rising incidence of cancer cases and the increasing importance of early and accurate diagnosis.

The increasing prevalence of cancer cases in the United States is the primary factor driving the escalating demand for cancer diagnostic tests. Given its status as a leading cause of morbidity and mortality, cancer necessitates the immediate implementation of advanced diagnostic technologies to facilitate timely detection and enhance therapeutic outcomes. Cancer of the breast is one of the most prevalent among women. Also on the rise is the incidence of colon cancer. The increasing incidence of colorectal cancer necessitates the implementation of supplementary screening tests in order to mitigate the disease's burden. This is the market growth driver.

Continuous advancements in diagnostic technologies have played a pivotal role in shaping the market for cancer diagnosis. Advancements such as next-generation sequencing, liquid biopsy, and molecular imaging have significantly enhanced the accuracy and precision of cancer detection, thereby fostering the adoption of these sophisticated diagnostic methods.

The growing emphasis on early cancer detection as a pivotal strategy to improve patient outcomes has generated a demand for diagnostic examinations that are both sensitive and accurate. Early detection enables timely intervention and individualized treatment plans, which contribute to increased cancer patient survival rates and enhanced quality of life.

With the advancement of personalized medicine, wherein treatment strategies are tailored to the distinct genetic profile of each individual patient, molecular diagnostics are assuming a critical role. By utilising molecular profiling and genetic testing, oncologists are capable of identifying particular genetic modifications, thereby facilitating the development of targeted treatments and improving overall prognoses. Personalized medicine is beginning to exceed the limitations of conventional medicine due to its foundation on the distinct genetic profile of each individual patient.

Increasingly, it empowers medical professionals to shift the emphasis from disease response to disease prevention. foresee the probability that an individual will contract a disease.

Public awareness campaigns and nationwide and local cancer screening initiatives have increased the demand for cancer diagnosis services. These initiatives seek to educate the public on the significance of routine screenings and diagnostic examinations, which can lead to the detection and treatment of cancer at an earlier stage.

A fundamental demographic trend, the escalating elderly population in the United States influences the demand for cancer diagnosis. Aging increases the risk of developing cancer. Therefore, as the elderly population increases, the total number of cancer cases rises. This indicates that improved methods of cancer diagnosis are more crucial for this age group.

The application of artificial intelligence in cancer diagnosis has emerged as a significant and influential development. By analyzing medical images, pathology slides, and molecular data, AI systems assist physicians in making accurate and prompt cancer diagnoses. This technology has the potential to revolutionize the diagnostic process by significantly improving both speed and accuracy.

Traditional diagnostic techniques, such as tumor marker analysis and biopsy, remain indispensable in the realm of cancer diagnosis. The continued necessity for these established diagnostic techniques persists, especially when it comes to confirming the presence of cancer, determining its subtype, and guiding treatment decisions.

The utilization of comprehensive cancer panels, which simultaneously analyze a multitude of genetic alterations and biological markers, has gained momentum. Completing the genomic profile of a tumor, these panels facilitate the identification of potential therapeutic targets and guide the selection of appropriate treatment strategies.

The emergence of partnerships between pharmaceutical and diagnostic companies has become a notable trend. These collaborative alliances aim to streamline the procedure for creating and introducing companion diagnostics to the market. The utilization of companion diagnostics is crucial in the identification of patients who are at the highest probability of exhibiting favorable responses to specific targeted treatments.

## Market Drivers

### Rising Incidence of Cancer

The increasing incidence of cancer in the US is a primary driver for the cancer diagnostics market. According to the American Cancer Society, approximately 1.9 million new cancer cases are expected to be diagnosed in 2025. This alarming trend necessitates the development and adoption of advanced diagnostic tools to facilitate early detection and improve patient outcomes. As the population ages, the demand for effective cancer diagnostics is likely to rise, prompting healthcare providers to invest in innovative technologies. The cancer diagnostics market is projected to grow significantly, with estimates suggesting a compound annual growth rate (CAGR) of around 7.5% from 2025 to 2030. This growth is driven by the urgent need for accurate and timely cancer detection methods, which are essential for effective treatment planning.

### Government Initiatives and Funding

Government initiatives aimed at improving cancer care significantly impact the cancer diagnostics market. The National Cancer Institute (NCI) and other federal agencies have increased funding for cancer research and diagnostic innovation. In 2025, the NCI's budget is projected to exceed $6 billion, with a substantial portion allocated to developing new diagnostic tools and technologies. These initiatives not only foster innovation but also encourage collaboration between public and private sectors, leading to the rapid advancement of diagnostic solutions. Furthermore, the establishment of programs that promote early detection and screening is likely to enhance the overall effectiveness of cancer diagnostics, thereby driving market growth. The cancer diagnostics market is expected to benefit from these strategic investments, which aim to reduce cancer mortality rates through improved diagnostic capabilities.

### Advancements in Diagnostic Technologies

Technological innovations play a crucial role in shaping the cancer diagnostics market. The introduction of next-generation sequencing (NGS), liquid biopsy, and artificial intelligence (AI) in diagnostic processes has revolutionized the way cancer is detected and monitored. These advancements enable more precise and less invasive testing methods, which are increasingly preferred by both patients and healthcare providers. For instance, liquid biopsy allows for the detection of circulating tumor DNA, providing insights into tumor dynamics without the need for invasive tissue biopsies. The market for these advanced diagnostic technologies is expected to reach approximately $20 billion by 2026, reflecting a growing recognition of their potential to enhance diagnostic accuracy and patient care in the cancer diagnostics market.

### Growing Demand for Personalized Medicine

The shift towards personalized medicine is reshaping the landscape of the cancer diagnostics market. As treatments become increasingly tailored to individual patient profiles, the need for precise diagnostic tools that can identify specific biomarkers is paramount. This trend is driven by the recognition that different cancer types and even individual tumors can respond differently to therapies. Consequently, the market for companion diagnostics, which are tests designed to determine the suitability of a particular treatment for a patient, is expanding rapidly. By 2027, the companion diagnostics segment is expected to account for over 30% of the total cancer diagnostics market. This growing demand for personalized approaches underscores the importance of advanced diagnostic technologies in ensuring optimal treatment outcomes for cancer patients.

### Increased Focus on Preventive Healthcare

The rising emphasis on preventive healthcare is a significant driver of the cancer diagnostics market. As awareness of the benefits of early detection grows, more individuals are seeking regular screenings and diagnostic tests. This trend is supported by various public health campaigns and initiatives aimed at educating the population about cancer risks and the importance of early intervention. In 2025, it is estimated that nearly 50% of adults in the US will participate in routine cancer screenings, reflecting a cultural shift towards proactive health management. This increased participation is likely to boost demand for diagnostic services and technologies, thereby propelling growth in the cancer diagnostics market. The focus on prevention not only enhances patient outcomes but also reduces the overall burden on healthcare systems.

## Future Outlook

The [Cancer Diagnostics Market](https://www.marketresearchfuture.com/reports/cancer-diagnostics-market-1962) is projected to grow at a 7.72% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising healthcare expenditure.

**New opportunities:**

- Development of AI-driven diagnostic tools for early detection Expansion of liquid biopsy technologies for non-invasive testing Partnerships with telehealth platforms for remote diagnostics

By 2035, the market is expected to achieve substantial growth, reflecting advancements in diagnostic technologies.

## Segment Insights

### By Test Type: Biopsy (Largest) vs. Molecular Testing (Fastest-Growing)

In the US cancer diagnostics market, the test type segment exhibits a diverse distribution of market shares. Biopsies hold a significant portion of this market, making it the largest segment due to their critical role in confirming cancer diagnoses. Imaging and blood tests, while essential, follow behind, with molecular testing rapidly gaining traction. This increasing reliance on precise diagnostic techniques reflects the evolving landscape of cancer diagnostics as professionals seek more accurate methods for patient evaluations.

The growth trends in this segment are primarily driven by advancements in technology and a heightened emphasis on early detection. Molecular testing is recognized as the fastest-growing area, propelled by innovations in personalized medicine and biomarker analysis. As healthcare providers focus on improving patient outcomes, the expansion of molecular diagnostics is fostering a shift towards more comprehensive cancer screening techniques, positioning it as a pivotal player in future cancer care strategies.

Biopsy (Dominant) vs. Molecular Testing (Emerging)

Biopsy, as the dominant segment, plays a central role in the cancer diagnostics process, allowing for direct tissue sampling and examination. Its established protocols and physician acceptance make it a preferred choice in clinical settings. In contrast, molecular testing, categorized as an emerging segment, is representative of a significant shift towards precision medicine. Utilizing advanced biological markers, it offers insights into genetic mutations that can influence treatment decisions. This segment is characterized by rapid technological advancements and increasing investments, making it a vital area for growth in the diagnostics landscape. The interplay between these two segments reveals a transitional phase in cancer diagnostics, where traditional methods coexist with innovative approaches, leading to enhanced patient care.

### By Cancer Type: Breast Cancer (Largest) vs. Lung Cancer (Fastest-Growing)

The US cancer diagnostics market exhibits a diverse distribution across various cancer types, with Breast Cancer dominating the segment. It holds a significant share, reflecting high awareness and screening initiatives. Lung Cancer follows, gaining attention due to increased prevalence, driven by smoking and environmental factors. Prostate and Colorectal Cancers also contribute to the market, but their shares are comparatively smaller; however, ongoing research and advancements in diagnostic methods are gradually elevating their profiles.

Growth trends are primarily influenced by technological advancements and rising healthcare expenditures. Notably, Lung Cancer stands out as the fastest-growing segment due to early detection methods and targeted therapies. As awareness of symptoms and risk factors improves, the demand for diagnostics in this segment increases. Stakeholders are focusing on enhancing existing technologies while expanding access to diagnostic services for all cancer types.

Breast Cancer (Dominant) vs. Lung Cancer (Emerging)

Breast Cancer remains the dominant segment in the diagnostics market, characterized by proactive screening programs and robust public health campaigns that encourage early detection. The array of diagnostic technologies employed, including mammography and advanced imaging, bolsters its market position. On the other hand, Lung Cancer is emerging rapidly, spurred by innovations in diagnostic techniques, such as molecular testing and liquid biopsies. As healthcare providers aim to tackle the high mortality rates associated with lung cancer, investments in diagnostic tools are intensifying. The increasing focus on personalized medicine and targeted therapies is further enhancing the potential for lung cancer diagnostics, making it a crucial area for future growth.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the US cancer diagnostics market, hospitals represent the largest end user segment, commanding a significant share of the overall market. With their advanced resources and access to cutting-edge technologies, hospitals are pivotal in offering a variety of cancer diagnostic services. Diagnostic laboratories, on the other hand, are witnessing rapid growth, driven by the increasing demand for specialized diagnostic tests and the development of innovative diagnostic technologies that improve accuracy and turnaround times.

The growth of the diagnostic laboratories segment is significantly influenced by the rising incidence of cancer and the growing awareness of early detection. Furthermore, advancements in molecular diagnostics and personalized medicine are propelling laboratories to expand their testing capabilities. The increasing collaboration between laboratories and healthcare providers is also fostering innovation and enhancing the quality of cancer diagnostics, making this segment an emerging force within the market.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals remain the dominant player in the US cancer diagnostics market, primarily due to their comprehensive infrastructure and ability to provide a wide range of diagnostic services under one roof. They are equipped with the latest technology and skilled professionals, allowing for effective cancer screening and diagnosis. In contrast, diagnostic laboratories are emerging as key contributors, focusing on specialized testing and innovative diagnostic solutions. They capitalize on the trend toward precision medicine, which emphasizes tailored treatment options based on individual genetic profiles. This shift towards personalized healthcare allows diagnostic laboratories to flourish, positioning them strategically within the market and meeting the rising demands for advanced diagnostic methodologies.

### By Sample Type: Tissue Samples (Largest) vs. Blood Samples (Fastest-Growing)

In the US cancer diagnostics market, Tissue Samples dominate the sample type segment, accounting for a significant share due to their extensive use in histopathological examinations. Following closely are Blood Samples, which have gained traction due to increasing adoption of liquid biopsies for early cancer detection. Urine Samples, while important, hold a smaller market share and are primarily used for specific types of cancers, limiting their overall impact in comparison to the other sample types.

Growth trends in this segment are influenced by advancements in diagnostic technologies such as next-generation sequencing and liquid biopsy methods. The shift towards minimally invasive procedures is propelling the demand for Blood Samples as a faster and less painful alternative to tissue biopsies. Moreover, increased funding for cancer research and higher awareness about early detection significantly contribute to the upward trajectory of the entire sample type segment.

Tissue Samples (Dominant) vs. Urine Samples (Emerging)

Tissue Samples are the dominant force in the US cancer diagnostics market, utilized primarily for their accuracy in providing definitive histological information. The reliability of these samples in diagnosing various cancer types ensures their continued prevalence in clinical settings. In contrast, Urine Samples are emerging, capturing attention due to their non-invasive nature and growing application in specific cancers like bladder cancer. Their development is supported by innovations in biomarker identification, making them a viable alternative for early detection and monitoring. While Tissue Samples remain the standard, Urine Samples are quickly gaining ground as diagnostics methods evolve.

## Competitive Benchmarking

The [cancer diagnostics](https://www.marketresearchfuture.com/reports/cancer-diagnostics-market-1962) market is characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of cancer, and a growing emphasis on early detection. Major players such as Roche (CH), Abbott (US), and Illumina (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Roche (CH) focuses on innovation through its robust pipeline of diagnostic tests, particularly in liquid biopsy technologies, which are gaining traction for their non-invasive nature. Abbott (US) emphasizes partnerships and collaborations to expand its diagnostic portfolio, while Illumina (US) is heavily investing in next-generation sequencing technologies, aiming to revolutionize genomic testing in oncology. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and strategic partnerships. Key business tactics within the cancer diagnostics market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation. The influence of major companies is significant, as they set trends that smaller firms often follow, particularly in terms of technological advancements and regulatory compliance. In October 2025, Roche (CH) announced the launch of its new liquid biopsy test, which is designed to detect multiple types of cancer at early stages. This strategic move is pivotal as it aligns with the growing demand for non-invasive diagnostic solutions, potentially positioning Roche as a leader in this emerging segment. The introduction of this test not only enhances Roche's product offerings but also reinforces its commitment to innovation in cancer diagnostics. In September 2025, Abbott (US) entered into a strategic partnership with a leading biotechnology firm to co-develop a novel biomarker for early cancer detection. This collaboration is significant as it underscores Abbott's strategy to leverage external expertise and accelerate the development of cutting-edge diagnostic solutions. By integrating innovative biomarkers into its existing portfolio, Abbott aims to enhance its competitive edge in the market. In August 2025, Illumina (US) expanded its collaboration with a prominent research institution to advance the application of genomic sequencing in cancer diagnostics. This initiative is crucial as it not only enhances Illumina's research capabilities but also positions the company at the forefront of personalized medicine. The focus on genomic data integration into clinical workflows is likely to drive future growth and innovation in cancer diagnostics. As of November 2025, current trends in the cancer diagnostics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI). Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient outcomes. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological innovation, reliability of supply chains, and the ability to deliver personalized solutions. This transition may redefine the competitive landscape, emphasizing the importance of agility and responsiveness in meeting the needs of healthcare providers and patients.

## Report Scope

| MARKET SIZE 2024 | 46.35(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 49.93(USD Billion) |
| MARKET SIZE 2035 | 105.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.72% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), Abbott (US), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Bristol-Myers Squibb (US), Illumina (US), Agilent Technologies (US), Qiagen (DE), Hologic (US) |
| Segments Covered | Test Type, Cancer Type, End User, Sample Type |
| Key Market Opportunities | Integration of artificial intelligence in cancer diagnostics enhances accuracy and efficiency in early detection. |
| Key Market Dynamics | Technological advancements drive innovation in cancer diagnostics, enhancing accuracy and efficiency in detection methods. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall valuation of the US cancer diagnostics market in 2024?**
A: The overall market valuation was $46.35 Billion in 2024.

**Q: What is the projected market valuation for the US cancer diagnostics market by 2035?**
A: The projected valuation for 2035 is $105.0 Billion.

**Q: What is the expected CAGR for the US cancer diagnostics market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 7.72%.

**Q: Which test type segment had the highest valuation in 2024?**
A: In 2024, the molecular testing segment had the highest valuation at $16.35 Billion.

**Q: What is the projected valuation for the blood tests segment by 2035?**
A: The projected valuation for the blood tests segment by 2035 is $25.0 Billion.

**Q: Which cancer type segment is expected to grow the most by 2035?**
A: The colorectal cancer segment is expected to grow the most, with a projected valuation of $36.0 Billion by 2035.

**Q: What was the valuation of the diagnostic laboratories segment in 2024?**
A: The valuation of the diagnostic laboratories segment was $15.0 Billion in 2024.

**Q: Which sample type segment is projected to have the highest valuation by 2035?**
A: The blood samples segment is projected to have the highest valuation at $45.0 Billion by 2035.

**Q: Who are the key players in the US cancer diagnostics market?**
A: Key players include Roche, Abbott, Thermo Fisher Scientific, Siemens Healthineers, Bristol-Myers Squibb, Illumina, Agilent Technologies, Qiagen, and Hologic.

**Q: What was the valuation of the breast cancer segment in 2024?**
A: The valuation of the breast cancer segment was $12.0 Billion in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-cancer-diagnostics-market-15825*